Travere Therapeutics
A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.
About
Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing transformative therapies for patients with rare diseases and conditions with high unmet medical need. The company's lead product candidate, pegtaralgene (CHTR-001), is in development for the treatment of nephropathic cystinosis. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does Travere Therapeutics do?
Travere Therapeutics is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare, Rare Diseases. It is based in San Diego, California, USA and was founded in 2015. Public records show about 125 people and $63M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Travere Therapeutics raised?
Travere Therapeutics has raised a total of $63M in funding. The most recent round on record is Convertible Note.
Where is Travere Therapeutics headquartered?
Travere Therapeutics is headquartered in San Diego, California, USA.
When was Travere Therapeutics founded?
Travere Therapeutics was founded in 2015.
What industry does Travere Therapeutics operate in?
Travere Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Rare Diseases, Drug Discovery.
How many employees does Travere Therapeutics have?
Travere Therapeutics has approximately 125 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.